1. Home
  2. CBAT vs ANVS Comparison

CBAT vs ANVS Comparison

Compare CBAT & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBAK Energy Technology Inc.

CBAT

CBAK Energy Technology Inc.

N/A

Current Price

$0.82

Market Cap

70.9M

Sector

Miscellaneous

ML Signal

N/A

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

N/A

Current Price

$1.82

Market Cap

76.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBAT
ANVS
Founded
1999
2008
Country
China
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
70.9M
76.6M
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
CBAT
ANVS
Price
$0.82
$1.82
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
263.8K
590.2K
Earning Date
05-18-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.39
EPS
N/A
N/A
Revenue
$195,189,306.00
N/A
Revenue This Year
$66.88
N/A
Revenue Next Year
$41.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.52
N/A
52 Week Low
$0.46
$1.54
52 Week High
$1.24
$5.50

Technical Indicators

Market Signals
Indicator
CBAT
ANVS
Relative Strength Index (RSI) 72.23 48.27
Support Level $0.77 $1.73
Resistance Level $0.89 $2.02
Average True Range (ATR) 0.08 0.10
MACD 0.02 -0.00
Stochastic Oscillator 75.46 25.39

Price Performance

Historical Comparison
CBAT
ANVS

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments; CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe, India, Africa, and other regions.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: